Collegium Pharmaceutical (COLL) Free Cash Flow Growth (3y) (2017 - 2026)
Powered by 
Analysis
Collegium Pharmaceutical (COLL) Free Cash Flow Growth (3y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 33.62% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | -20.26% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 17.80% |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 17.73% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 28.91% |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 56.97% |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 18.29% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 49.44% |
| 10 | Collegium Pharmaceutical | 753.09 Mn | 603.77 Mn | 110.29 Mn | -10.76% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -10.76% |
| Mar 31, 2026 | 27.39% |
| Dec 31, 2025 | 23.23% |
| Sep 30, 2025 | 22.42% |
| Jun 30, 2025 | 21.86% |
| Mar 31, 2025 | 60.67% |
| Dec 31, 2024 | 33.07% |
| Sep 30, 2024 | -36.52% |
| Jun 30, 2024 | 32.57% |
| Mar 31, 2024 | 44.97% |
| Dec 31, 2023 | 51.37% |
| Sep 30, 2023 | 32.52% |
| Jun 30, 2023 | 32.31% |
| Mar 31, 2023 | 78.25% |
| Dec 31, 2022 | 64.21% |
| Sep 30, 2022 | 108.32% |
| Jun 30, 2022 | 42.73% |
| Mar 31, 2022 | -28.82% |
| Dec 31, 2021 | -4.14% |
| Sep 30, 2021 | -24.29% |